Novo Nordisk reports CagriSema data. Novo Nordisk stock costs EUR 35.03
Published on 10/25/2026 at 17:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCagriSema findings and next session
- Novo Nordisk reported CagriSema weight-loss findings on October 20, 2026, with 25 percent average weight loss among women.
- Novo Nordisk stock trades in weekend trading at Lang & Schwarz at EUR 35.03 at 5:54 p.m. CEST on October 25, 2026.
- The next Xetra session is scheduled for October 26, 2026.
On October 20, 2026, Novo Nordisk reported that CagriSema was associated with 25 percent average weight loss among women in a post hoc analysis of the REDEFINE 1 study. At Lang & Schwarz, the stock was EUR 35.03 at 5:54 p.m. CEST on October 25, 2026.
Market context: Latest market reports.
Weekend trading at Lang & Schwarz
The Lang & Schwarz price for Novo Nordisk was EUR 35.03 at 5:54 p.m. CEST on October 25, 2026. The quote was recorded during weekend trading. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novo Nordisk stock.
The week in figures
The documented weekend-trading quote was EUR 35.03 at Lang & Schwarz on October 25, 2026. The available company update during the period concerned CagriSema data from October 20, 2026.
Chronology of the week
On October 20, 2026, Novo Nordisk said CagriSema was associated with 25 percent average weight loss among women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting, according to the company's newsroom.
Dates of the coming week
The next Xetra session is scheduled for October 26, 2026. Novo Nordisk's newsroom lists no additional dated company announcement in the fetched material for the coming week.
